Company Overview and News

RBR Group shows it is positioned to benefit with contract win

RBR Group Ltd (ASX:RBR) has secured contracts with combined revenues of almost $500,000 for skills training in Mozambique.

RBR Group targets cash injection

RBR Group (ASX:RBR) has been granted a trading halt by the ASX, pending details of a fundraising initiative.

RBR Group Ltd to offer shares

The halt will remain in place until the opening of trade on Friday 25th November 2016, or earlier if an announcement is made to the market.

RBR Group Ltd wins first commercial training contract in Mozambique

RBR Group Ltd (ASX:RBR) has secured its first commercial training contract in Mozambique to provide vocational training to the employees and contractors of Sasol Ltd (JSE:SOL). RBR’s Mozambican training subsidiary, Futuro Skills has been contracted to provide vocational training in two technical disciplines at Sasol’s facilities in the Inhambane Province. Futuro Skills has an existing training facility in Maputo with plans to develop an additional facility in Pemba, the heart of Mozambique’s emerging resources industry.

RBR Group Ltd partners with Site Group to train Mozambique’s workforce

RBR Group Ltd (ASX:RBR) formerly is a service provider to the resources, construction and oil & gas sectors.

RBR Group Ltd finalises purchase of Registered Training Organisation

RBR Group Ltd (ASX:RBR) formerly is a service provider to the resources, construction and oil & gas sectors.

Futuro Skills Market Update


Becoming a substantial holder


Half Year Accounts


RBR Group spreads its wings with RTO accreditation

Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...